Moderna (MRNA) stock is plunging Thursday after the COVID-19 vaccine maker announced plans to slash research and development (R&D) expenses and instead focus on receiving approvals for the many drugs in its pipeline.
Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus to winning approvals for the 10 products in its pipeline.
"Moderna now has five respiratory vaccines with positive Phase 3 results and expects to submit three for approval this year," said Moderna CEO Stéphane Bancel in a statement. "In addition, we have five non-respiratory products in pivotal studies across cancer, rare diseases and latent vaccines with potential for approval by 2027."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Bancel adds that "the size of our late-stage pipeline combined with the challenge of launching products means we must now focus on delivering these 10 products to patients, slow down the pace of new R&D investment, and build our commercial business."
The shift in strategy comes as Moderna has seen a sharp decline in sales of its COVID-19 vaccine, including a 37% year-over-year decrease in its most recent quarter.
In the release, Moderna also said it anticipates fiscal 2025 revenue to be in the range of $2.5 billion to $3.5 billion and sales to grow at a 25% compound annual growth rate from 2026 to 2028, "driven by new product launches."
The midpoint of MRNA's revenue outlook for its upcoming fiscal year, $3 billion, came in well below analysts' expectations. Wall Street is expecting revenue of $3.74 billion in fiscal 2025, according to Yahoo Finance.
Is Moderna stock a buy, sell or hold?
Moderna had a good run up the price charts to start 2024, but the healthcare stock is now down 33% for the year to date. Still, Wall Street remains bullish on the drugmaker.
According to S&P Global Market Intelligence, the consensus analyst target price for MRNA stock is $125.71, representing implied upside of more than 90% to current levels. Additionally, the consensus recommendation is Buy. However, analysts may revise their targets lower following the reaction to its updated R&D plans.
And some analysts are already on the sidelines when it comes to the large-cap stock, including financial services firm William Blair, which has a Market Perform rating (equivalent to a Hold) on MRNA.
"Like other biotechnology companies with development pipelines, Moderna's risks center on commercial, regulatory, and clinical development," said William Blair analyst Myles Minter in an August 16 note.
The analyst adds that key risks specific to Moderna include the "potential for greater-than-anticipated drop-off in the COVID market, possible failure to show equivalent efficacy across various flu strains versus currently available and other emerging flu vaccines, poor tolerability and/or efficacy with repeat mRNA therapeutics dosing, and other potential clinical setbacks including failed or delayed trials."
Related Content
-
How to Rank Your Financial PrioritiesCircumstances are different for everyone, but this adviser with 20-plus years of experience shares some insights on getting your financial priorities in order.
-
Can You Define Baby Boomers? Look at Trump and HarrisTrump and Harris are bookends of the sprawling Baby Boomer generation, which spans 18 years. No wonder they have different world views.
-
How to Rank Your Financial Priorities
Circumstances are different for everyone, but this adviser with 20-plus years of experience shares some insights on getting your financial priorities in order.
-
Medicare or Medicare Advantage: Which Is Right for You?From overall costs to availability of care, here's what to know about the differences between traditional Medicare and Medicare Advantage plans.
-
Wealth Is More Than Just Your Money: How to Manage It AllIn addition to handling your financial wealth, consider ways to manage your non-financial assets: health, knowledge, time and relationships.
-
Stock Market Today: Stocks Hit Fresh Highs on Bank Earnings, Econ NewsStrong corporate profits and benign economic data once again sent equities to record levels.
-
You're 60 Years Old With $1 Million Saved: Can You Retire?The answer depends on several factors. The key is to create a plan that combines all aspects of retirement — income, taxes, health care and legacy planning.
-
Are You a Danger When You Drive?You might be shaking your head no, but read on for the five things that most of us have at some point done, or are doing, that could cause an accident.
-
Stock Market Today: Markets Slip on Hot Inflation Print, Layoff NewsEconomic data continues to complicate expectations for Federal Reserve rate cuts.
-
CPI Report Points to Gradual Pace for Rate Cuts: What the Experts Are SayingCPI Inflation surprised to the upside last month but the disinflation trend remains on track.
